

Advancing Health Care Investments in Key Markets: Coherus BioSciences, LGC, and Panasonic Healthcare

Across the health care spectrum, KKR portfolio companies are moving the needle by creating innovative health care solutions and systems, advancing diagnostic capabilities, and researching cures. Our portfolio companies are creating meaningful products and making discoveries that have the potential to minimize or eradicate a variety of diseases

or chronic conditions for future generations. Our Firm’s deep knowledge in the health care industry, a long history of successfully investing in this field, and a wide network of relevant relationships position us to facilitate growth and operational enhancements in these companies around the world.

Coherus BioSciences: Biosimilar Drugs¹

Headquartered in Redwood City, California, U.S., Coherus BioSciences is a leader in developing and commercializing biosimilar drugs of the highest quality and value. Regulators in the United States, Europe, and Asia support this new pharmaceutical category, which develops almost identical replicas of biologic drugs. As the cost of drugs is rising, the development of biosimilars is beneficial because the drugs are offered at a lower cost and therefore potentially lead to broader access. Coherus BioSciences has a rich pipeline of biosimilar therapeutics that will have a major impact on patient access when the products hit the market.

LGC: Science for a Safer World¹

Headquartered in London, UK, LGC is a life sciences measurement and testing company with a global presence in the reference materials, proficiency testing, genomics, and laboratory services markets. With a vision of “Science for a Safer World,” the company has services and products that seek to support public safety, health, and security. LGC has experienced significant growth during the past five years, and KKR has continued to invest behind its growth potential since acquiring the company in late 2015. KKR Capstone² is aiding in the commercial development of the genomics business, which develops and manufactures products critical to helping plant breeders develop crops to feed the world’s growing population and molecular diagnostics companies understand the genetics of illnesses such as cancer and infectious diseases. In addition to this, LGC’s reference materials and lab services are used around the world to ensure the safety of many daily and essential products, including pharmaceuticals and food supplements.

Panasonic Healthcare: Solutions for Personalized Health Care¹

Panasonic Healthcare is a leading provider of diabetes monitoring systems and specialized laboratory equipment worldwide, as well as clinical health care IT systems in Japan. The company centers its business on three key themes:

- linking diagnosis and treatment
- utilizing medical information
- supporting drug development and life science research

The company provides localized solutions from its global platform across areas such as biomedical product development and medical information systems integration. With its acquisition of Bayer AG’s global Diabetes Care business, now called Ascensia Diabetes Care, Panasonic Healthcare will provide high-quality solutions and precision tools to people with diabetes in more than 125 countries. Panasonic Healthcare is focused not only on providing solutions for personalized health care to people around the world but also on improving the energy efficiency of its facilities and has been tracking the results of these efforts as part of KKR’s Green Solutions Platform.

¹ The above are for illustrative purposes only and are not representative of all investments made by KKR Funds or accounts, nor should it be assumed that any investment in the companies identified were or will be profitable.

² KKR Capstone is not an affiliate or subsidiary of KKR. Please see kkr.com/our-firm/kkr-capstone for additional disclosure regarding KKR Capstone.